ArticlePharmaceutics2026

Enhanced Payload Release Enables Disitamab Vedotin to Surpass Trastuzumab Emtansine and Retain Efficacy in Acquired Resistance to Clinical Anti-HER2 Therapies.

Mónica Redondo-Puente et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.